Evidence map›Paper›PMID 42212523›Full record

ReviewJournal of cell science2026

Amoeboid cancer cells at a glance.

Ritobrata Ghose, Victoria Sanz-Moreno

Abstract readReview
In one paragraph

Review in Journal of cell science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ritobrata GhoseCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Victoria Sanz-MorenoCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.ORCID 0000-0002-5096-9456

Funding

Breast Cancer NowCancer Research UK A24478Cancer Research UK C33043Institute of Cancer Research
6 · The paper itself

Abstract

Amoeboid behaviour represents a distinct and clinically significant cancer cell state within the epithelial-to-mesenchymal transition (EMT) spectrum. Defined by the loss of cell-cell junctions and adoption of a rounded morphology, amoeboid cancer cells exhibit low adhesion and rely heavily on Rho-ROCK-myosin II-mediated cortical contractility. This combination of high contractility and reduced adhesion enables rapid migration through dense, confining environments, using blebs as functional protrusions. This behaviour is commonly observed at tumour invasive fronts, within metastatic deposits and among therapy-resistant cell populations. Amoeboid identity integrates multiple biochemical signalling programmes alongside mechanical cues such as confinement, matrix topography and shear stress. Collectively, these factors drive a highly plastic state characterised by stem-cell-like traits, metabolic adaptability, low oxidative stress and an immunosuppressive secretome. Such features confer strong metastatic potential and broad resistance to therapy, underpinned by core physicochemical dependencies on cortical tension, membrane mechanics and redox balance. This Cell Science at a Glance article and the accompanying poster highlight these defining characteristics, establishing amoeboid behaviour as a crucial driver of cancer progression and an increasingly promising therapeutic target.

Indexed as

AmoebaEpithelial-Mesenchymal TransitionNeoplasmsAnimalsCell AdhesionCell MovementHumansAmoeboid cancer cellsCytoskeletonImmunomodulationMechanobiologyMetastasis

Identifiers

PMID42212523
PMCPMC13286362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.